Loading clinical trials...
Loading clinical trials...
An Outpatient Medical Abortion Regimen With Mifepristone and Two Doses of Misoprostol at 71-77 and 78-84 Days of Pregnancy
This study seeks to evaluate the efficacy, side effect profile and acceptability of a medical abortion regimen with mifepristone and two doses of 800 mcg misoprostol buccally at 71-77 and 78-84 days of gestation to further expand the evidence base for the most effective regimens in the late first trimester of pregnancy.
Age
11 - 55 years
Sex
FEMALE
Healthy Volunteers
Yes
University of Hawaii
Hilo, Hawaii, United States
University of Hawaii
Honolulu, Hawaii, United States
Planned Parenthood North Central States
Saint Paul, Minnesota, United States
Philadelphia Women's Center
Philadelphia, Pennsylvania, United States
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky
Federal Way, Washington, United States
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky
Tacoma, Washington, United States
Start Date
October 7, 2022
Primary Completion Date
June 30, 2023
Completion Date
June 30, 2023
Last Updated
July 25, 2023
23
ACTUAL participants
Mifepristone + 2 doses of misoprostol 800 mcg
DRUG
Lead Sponsor
Gynuity Health Projects
Collaborators
NCT06708208
NCT06795334
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04941443